A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC).

Aroldi F, Elez E, André T, Perkins G, Prenen H, Popovici V, Gallagher P, Houlden J, Collins L, Roberts C, Rolfo C, Di Nicolantonio F, Grayson M, Boyd R, Bettens K, Delfavero J, Coyle V, Lawler M, Khawaja H, Laurent-Puig P, Salto-Tellez M, Maughan TS, Tabernero J, Adams R, Jones R, Hennessy BT, Bardelli A, Peeters M, Middleton MR, Wilson RH, Van Schaeybroeck S, MErCuRIC Trial Consortium

Open source

DOI: 10.1186/s12885-025-14068-1
Published: 2025 Apr 10
Container: BMC cancer
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12885-025-14068-1,
  title = {A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC).},
  author = {Aroldi F and Elez E and André T and Perkins G and Prenen H and Popovici V and Gallagher P and Houlden J and Collins L and Roberts C and Rolfo C and Di Nicolantonio F and Grayson M and Boyd R and Bettens K and Delfavero J and Coyle V and Lawler M and Khawaja H and Laurent-Puig P and Salto-Tellez M and Maughan TS and Tabernero J and Adams R and Jones R and Hennessy BT and Bardelli A and Peeters M and Middleton MR and Wilson RH and Van Schaeybroeck S and MErCuRIC Trial Consortium},
  year = {2025},
  journal = {BMC cancer},
  doi = {10.1186/s12885-025-14068-1},
  url = {https://doi.org/10.1186/s12885-025-14068-1}
}

RIS

TY  - JOUR
TI  - A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC).
AU  - Aroldi F
AU  - Elez E
AU  - André T
AU  - Perkins G
AU  - Prenen H
AU  - Popovici V
AU  - Gallagher P
AU  - Houlden J
AU  - Collins L
AU  - Roberts C
AU  - Rolfo C
AU  - Di Nicolantonio F
AU  - Grayson M
AU  - Boyd R
AU  - Bettens K
AU  - Delfavero J
AU  - Coyle V
AU  - Lawler M
AU  - Khawaja H
AU  - Laurent-Puig P
AU  - Salto-Tellez M
AU  - Maughan TS
AU  - Tabernero J
AU  - Adams R
AU  - Jones R
AU  - Hennessy BT
AU  - Bardelli A
AU  - Peeters M
AU  - Middleton MR
AU  - Wilson RH
AU  - Van Schaeybroeck S
AU  - MErCuRIC Trial Consortium
PY  - 2025
JO  - BMC cancer
DO  - 10.1186/s12885-025-14068-1
UR  - https://doi.org/10.1186/s12885-025-14068-1
ER  -

APA

F, A., E, E., T, A., G, P., H, P., V, P., P, G., J, H., L, C., C, R., C, R., F, D. N., M, G., R, B., K, B., J, D., V, C., M, L., H, K., P, L., M, S., TS, M., J, T., R, A., R, J., BT, H., A, B., M, P., MR, M., RH, W., S, V. S., & Consortium, M. T. (2025). A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC).. BMC cancer. https://doi.org/10.1186/s12885-025-14068-1

Source records

pubmed · retrieved 2026-09-26T18:06:15.324Z
europe-pmc · retrieved 2026-09-26T18:06:15.346Z
doaj · retrieved 2026-09-26T18:06:15.350Z
hal · retrieved 2026-09-26T18:06:15.365Z